Translational Bioinformatics and Experimental Approaches to Advance Drug Repositioning and Combination Therapy Development for Alzheimers Disease and Related Dementias (R01 Clinical Trial Not Allowed)
Open to U.S. universities, research institutions, nonprofits, foreign organizations, and certain government/tribal entities. This NIH R01 funds preclinical mouse-model testing of repurposed or inve…
- Deadline
- May 7, 2028
- Posted
- Dec 30, 2024
- Award amount
- Up to $1,000,000
- Focus areas
- Health
Don’t miss this deadline
We’ll email you before May 7, 2028 so you have time to apply.
In plain English
Open to U.S. universities, research institutions, nonprofits, foreign organizations, and certain government/tribal entities. This NIH R01 funds preclinical mouse-model testing of repurposed or investigational drugs — alone or with non-drug interventions — for Alzheimer's disease and related dementias. Awards up to about $1,000,000.
AI-generated summary to help you decide quickly — verify the official eligibility rules before applying.
Who can apply
Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession.
About this grant
This Notice of Funding Opportunity (NOFO) invites applications that propose to use mouse models to conduct rigorous preclinical testing of drugs or drug combinations currently used for other conditions, as well as investigational drugs at various stages of clinical development, predicted to be efficacious in AD/ADRD. This initiative will also support preclinical testing of repurposable or investigational drug candidates in combination with non-pharmacologic interventions leading to robust translational outcomes. The central goal is to establish robust proof of concept that will enable rational drug repurposing and combination therapy development for the treatment and prevention of AD/ADRD.
Let AI draft your application
Your first draft is free: a narrative and budget outline tailored to this grant, emailed to you. Drafts are written in a nightly batch, so it arrives by email later — not instantly on this page.
Application Kit — $49 one-time
Winner intelligence + a first-draft narrative grounded in applications that actually won. One payment, no subscription.
Get the Application Kit →Related grants
Other open grants funding Health — soonest deadline first.
NHLBI Early Phase Clinical Trials for Therapeutics and/or Diagnostics for HLBS Disorders (R33 CT Required)
National Institutes of Health · Up to $1.5M · Due Jan 7, 2027
National Cancer Institute's Investigator-Initiated Early Phase Clinical Trials for Cancer Treatment and Diagnosis (R01 Clinical Trial Required)
National Institutes of Health · Up to $500K · Due Jan 7, 2027
Academic-Industrial Partnerships (AIP) to Translate and Validate In Vivo Imaging Systems (R01 Clinical Trial Optional)
National Institutes of Health · Up to $500K · Due Jan 7, 2027
Sustained Support for Informatics Technologies for Cancer Research and Management (U24 Clinical Trial Optional)
National Institutes of Health · $50K–$600K · Due in 2 days
Advanced Development of Informatics Technologies for Cancer Research and Management (U24 Clinical Trial Optional)
National Institutes of Health · $50K–$600K · Due in 2 days
GREGoRi Data Coordination and Outreach Center (U01, Clinical Trials Not Allowed)
National Institutes of Health · Up to $1.3M · Due in 13 days
Also listed under National Institutes of Health and Health Grants.
Source: public records via Grants.gov. UseGrants is an independent aggregator, not affiliated with any funding agency. Always confirm details on the official listing before applying.